Ligand Pharmaceuticals
Business Services · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
555 Heritage Dr Ste 200, Jupiter, Florid...Phone Number
(858) 550-7500Website
www.ligand.comRevenue
$274.5 MillionStock Symbol
LGNDIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
2
2
1
About Ligand Pharmaceuticals
Founded in 1987, Ligand Pharmaceuticals biopharmaceutical company focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's partner programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. The company is headquartered in San Diego, California.Explore more
Ligand Pharmaceuticals Org Chart
KR
Senior Vice President, Investments and Head, ...
MV
Bd Vice President, Investments
LH
Investment Analytics Vice President, Strategi...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ligand Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Ligand Pharmaceuticals has new funding data
Ligand Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Ligand Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Click to see if Ligand Pharmaceuticals had a recent Job posting/layoffs
Earning: See what the market has to say on Ligand Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Check out if Ligand Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Ligand Pharmaceuticals
Product Launch: Get notified when Ligand Pharmaceuticals launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Ligand Pharmaceuticals
Compare insights from companies similar to Ligand Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ligand Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ligand Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ligand Pharmaceuticals.
Ligand Pharmaceuticals financials insights
Gather financial insights about Ligand Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Debt
$6M
Ligand Pharmaceuticals Tech Stack
A closer look at the technologies used by Ligand Pharmaceuticals
See more technologies
Most Recent Scoops
Earnings
Ligand Pharmaceuticals has reported total revenue of USD 64 million for Q2, a 34% increase over the same period of the prior year, driven primarily by growth from FILSPARI, Ohtuvayre, and ZELSUVMI, with total royalties of USD 48 million and adjusted EPS of $2.37 per share, representing a 48% increase over the prior period.
Earnings, Finance
Project
Ligand Pharmaceuticals has outlined a catalyst calendar with up to seven pivotal study readouts expected by end of 2027, including OJEMDA, mezagitamab, osevampa, toravelixibat, and ursodiol, alongside anticipated milestones including one major FDA approval for Keytruda and rapamycin, continued geographic expansion for Ohtuvayre in China, potential FILSPARI approval in Japan, and OJEMDA approval in pediatric low-grade glioma.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Ligand Pharmaceuticals announced that Palvella's Phase III trial for its topical rapamycin drug targeting microcystic lymphatic malformations surpassed its upside scenario on both primary and secondary endpoints, with a rolling NDA submission expected to be complete by year-end and anticipated FDA approval in H1 2027, for which Ligand Pharmaceuticals receives a tiered royalty of 8% to 9.8%.
Pharmaceuticals, Clinical Operations
Project
expects up to seven pivotal trial readouts over the next 18 months, including Orchestra BioMed's AVIM Therapy in cardiovascular disease, OJEMDA in frontline pediatric low-grade glioma, lasofoxifene in metastatic ER-positive HER2-negative breast cancer, mezagitamab in immune thrombocytopenia and IgA nephropathy, osavampator in major depressive disorder, ersodetug in tumor hyperinsulinism, and volixibat in primary biliary cholangitis.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Audit, Legal Affairs, Acquisitions, Finance, Financial Operations
Ligand Pharmaceuticals News & Media
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
Ligand Pharmaceuticals (NASDAQ:LGND) outlined its royalty-focused growth strategy, recent XOMA acquisition and portfolio catalysts during a company presentation, highlighting a larger commercial-stage asset base and planned investment capacity. Chief Financial Officer Tavo Espinoza said Ligand hasLigand to Participate in September Investor Conferences
Ligand to Participate in September Investor ConferencesLGND: XOMA Acquisition Closed - Zacks Small Cap Research
By John Vandermosten, CFA NASDAQ: LGND READ THE FULL LGND RESEARCH NOTE Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported second quarter 2026 results boasting total revenue and income of $63.7 million, a 34% year over year increase. Adjusted core earnings per share (EPS) of $2.37 were also impressive, rising 48%. By line item, royalties rose 32%, and contract revenue increased by 161%.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ligand Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Founded in 1987, Ligand Pharmaceuticals biopharmaceutical company focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's partner programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasti... Read More
